Health Care Worker Perspectives of HIV Pre-exposure Prophylaxis Service Delivery in Central Uganda

Timothy R. Muwonge 1*, Rogers Nsubuga 1, Norma C. Ware 2, Monique A. Wyatt 2, Emily Pisarski 2, Brenda Kamusime 1, Vicent Kasiita 1, Grace Kakoola Nakwago 1, Charles Brown 1, Agnes Nakyanzi 1, Monica Bagaya 1, Felix Bamba 1, Timothy Ssebuliba 1, Ely Katabira 3, Peter Kyambadde 4,5, Jared M. Baeten 6,7, Renee Heffron 6, Connie Celum 6, Andrew Mujugira 1 and Jessica E. Haberer 2,8

1 Infectious Diseases Institute, Makerere University, Kampala, Uganda, 2 Harvard Medical School, Boston, MA, United States, 3 Department of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda, 4 Most At-Risk Populations Initiative, Kampala, Uganda, 5 STD/AIDS Control Program, Ministry of Health, Kampala, Uganda, 6 Departments of Global Health and Epidemiology, University of Washington, Seattle, WA, United States, 7 Gilead Sciences, Foster City, CA, United States, 8 Center for Global Health, Massachusetts General Hospital, Boston, MA, United States

Background: Scale-up of HIV pre-exposure prophylaxis (PrEP) services in Uganda is ongoing. However, health care workers (HCWs) may not be aware of PrEP nor what offering this service entails. We explored the impact of standardized HCW training on the knowledge and perspectives of PrEP service delivery in Uganda.

Methods: We recruited HCWs from facilities that offered HIV-related services in Central Uganda. Using the Uganda Ministry of Health curriculum, we trained HCWs on PrEP services. We collected data about PrEP knowledge, preparedness, and willingness to deliver PrEP to multiple key populations before the training, immediately after the training, and >6 months later (exit). We additionally conducted 15 qualitative interviews after the exit survey. Quantitative data were analyzed by Fisher exact test, while qualitative interview data were analyzed inductively.

Results: We recruited 80 HCWs from 35 facilities in urban (N = 24, 30%), peri-urban (N = 30, 37%), and rural (N = 26, 33%) areas. Most HCWs were nurse counselors (N = 52, 65%) or medical/clinical officers (N = 15, 18%). Surveys indicated that awareness of PrEP increased after the training and remained high. Knowledge of PrEP (i.e., as an effective, short-term antiretroviral medication to use before HIV exposure for people at high risk) generally increased with training, but significant gaps remained, and knowledge decreased with time. Most HCWs recommended PrEP for female sex workers and HIV serodifferent couples, as well as other key populations. We observed increases in the number of HCW who felt their facility was prepared to cater for HIV prevention and provide PrEP, but this view was not universal. HCWs believed in PrEP effectiveness and embraced it as an additional HIV prevention method. Concerns included patient adherence and behavioral risk compensation. HCWs noted challenges in PrEP delivery in terms of inadequate clinic preparedness, infrastructure, staff capacity, and poor attitudes toward key populations by untrained health workers. They felt further training was needed to ensure a smooth scale-up of services without stigmatization.
INTRODUCTION

Oral pre-exposure prophylaxis (PrEP) using tenofovir (TDF) and emtricitabine (FTC) co-formulated as a once-daily pill has demonstrated effectiveness against the acquisition of HIV infection (1, 2) and is recommended for HIV-negative persons at high risk of infection (3). Although PrEP is being scaled up globally, uptake in some settings is suboptimal, partly due to gaps in public health messaging and low awareness among healthcare workers (HCWs) (4). In Uganda, PrEP has been rolled out in a phased manner, first among HIV serodifferent couples and later expanded to other key populations that include men who have sex with men (MSM), sex workers, people who inject drugs, fisherfolk, transgender populations, adolescent girls and young women, and truck drivers (5).

Training of healthcare workers (HCWs) is a critical step in the rollout of new HIV prevention interventions including oral PrEP, especially given concerns about limited knowledge in HCWs and associated reluctance to recommend the use of PrEP to potential users (6, 7). For instance, in a study conducted to investigate perceptions and attitudes about prescribing PrEP among 311 HIV specialists in Italy, a negative attitude toward PrEP was significantly associated with lack of familiarity with information on, and prescription of, PrEP (8). In sub-Saharan Africa, a positive attitude and confidence to prescribe PrEP has been seen among some HCWs who have undergone training on HIV prevention service provision; feedback from these trainings is an important tool for the design of materials, content, and the national approach to training (9–11). Additional gaps in HCW training exist that must be filled to improve quality assurance of PrEP service delivery (12, 13).

The Uganda Ministry of Health (MoH) has made standardized training materials available to promote provision of PrEP (14, 15), yet the impact of this training on HCW PrEP knowledge has not been previously evaluated. We used mixed methods to assess HCW knowledge, preparedness, and willingness to deliver PrEP to key populations in central Uganda before, immediately after, and at least 6 months after training on PrEP service delivery.

METHODS

The Barriers Study

The Barriers Study was a mixed-methods study designed to assess knowledge of PrEP and identify potential barriers and facilitators of PrEP uptake and adherence among potential PrEP users, as well as to determine HCW knowledge of PrEP and perceptions regarding preparedness and willingness to deliver PrEP services in Central Uganda. Findings on potential PrEP users are described elsewhere (16); this paper focuses on the impact of HCW training. All activities associated with HCWs occurred in English (the official language used in provision of medical care in Uganda).

Recruitment

At the time of the study (2018), Central Uganda had 504 HIV care and treatment health facilities, including government health centers, sexually transmitted infection/HIV clinics offering HIV testing and treatment services, HIV serodifferent couple community-based organizations, and non-governmental organizations. We stratified health centers in roughly equal proportions by urban, peri-urban, and rural locations within the central region of Uganda from which we purposively selected a sample of 35 health centers that were felt to be representative of planned routine PrEP delivery sites. This site selection approach was based on characteristics of the existing PrEP sites (i.e., Health Center III or Health Center IV that were offering HIV prevention care and treatment to more than 100 persons registered in the facility HIV registers). Six government-supported facilities were already providing PrEP as part of a pilot program and were excluded from this study. We contacted the leadership of the selected health centers and asked them to identify up to three HCWs who were providing HIV prevention, care, and treatment services. These HCWs were selected from the cadres of administration, laboratory personnel, pharmacists, midwives, nurse counselors, and medical/clinical officers (N.B., medical officers have completed undergraduate medical training, whereas clinical officers have a diploma in medicine). Written invitations were sent to the HCWs asking them to take part in the study, which entailed a baseline survey just before a two-day training on PrEP service delivery plus surveys immediately after the training and at least 6 months later (exit). From the sample of HCWs that completed exit surveys, we purposively selected HCWs for in-depth qualitative interviews based on cadre and designation at the health facilities.

HCW Training

In January 2018, we invited all HCWs to attend a two-day training on PrEP service delivery that took place at the Infectious Diseases Institute training hub in Kampala, Uganda. We conducted three trainings, each of which included representation from the three geographical regions (i.e., urban, peri-urban, and rural). HCW training was led by a national trainer and focused on PrEP knowledge and service delivery based on Uganda MoH guidelines and training materials (5, 14, 15). Educational methods included both didactic sessions and role-plays. Training modules included: (1) PrEP basics...
PrEP, identifying people at substantial risk of HIV infection; (2) PrEP screening and eligibility (e.g., PrEP eligibility criteria, screening for substantial HIV risk and PrEP eligibility, PrEP contraindications, acute HIV infection); (3) Initial and follow-up visit requirements (e.g., visit procedures, national HIV testing guidelines, PrEP counseling), and; (4) PrEP stigma, side effects, and HIV seroconversion (e.g., creatinine elevation, strategies to minimize PrEP stigma, seroconversion management), as previously described (16).

Quantitative Surveys

Quantitative survey questionnaires focused on: (1) HIV prevention knowledge and what methods are being used at the facility; (2) PrEP knowledge, attitudes, and willingness to prescribe PrEP, and (3) provision, support, and preparedness for PrEP service delivery. Authors TRM and JEH developed the questions for the surveys based on the national PrEP guidelines (5). Items were pretested among research staff who were not part of the study team for clarity and relevance. Pre-specified options were given for each question, but participants could also indicate other responses. Trained research assistants administered the surveys individually with each HCW.

Qualitative Interviews

At the study exit visit, we conducted in-depth interviews among selected HCWs that explored their experiences and perspectives on: (1) the PrEP training they had received in the study; (2) their attitudes and knowledge of PrEP, including adherence; and (3) PrEP delivery and implementation, including a comparison of PrEP to other HIV prevention measures. The interview guide (see Appendix 1) was pilot tested among the research team. All interviews were conducted in a private space by social scientists (VK or BK, both trained in qualitative methods) and were scheduled at convenient times and venues. All interviews were audio-recorded, with permission, using a digital audio recorder.

Quantitative Analysis

We carried out an exploratory analysis, with the sample size reflecting available resources. Given the small sample size, we used Fisher’s exact test for all comparisons between and among categorical variables. In post-hoc analyses, we used univariable multinomial logistic regression to determine which comparisons were driving the significance. In these analyses, we compared each survey type (i.e., pre-training, post-training, or exit) as the exposure variables and the question response as the outcome. Data analyses were performed using Stata 14 (StataCorp, College Station, TX).

Qualitative Analysis

Each interview was transcribed by the interviewer and reviewed by a second researcher for quality. We analyzed each interview question inductively (17), utilizing Dedoose software (version 8.0.35). We developed a codebook that allowed for exploration of emergent content reflecting the experiences from the HCW’s perspectives. The initial five transcripts were coded independently by four coders (BK, VK, GK, and JM) who reviewed inconsistencies until consensus was reached. The final codebook was then applied to all transcripts. Coded data were sorted by codes, re-reviewed, and grouped based on similar content. Concepts were selected to correspond to and contextualize the quantitative findings. Results are presented below, with illustrations from interview excerpts. Saturation of qualitative findings was achieved. Results were not presented to participants for feedback.

Ethical Considerations

We obtained ethics approval from the National HIV/AIDS Research Committee (ARC 196), the Uganda National Council for Science and Technology (SS 4277), and Partners HealthCare/Massachusetts General Hospital (2017P000482/PHS). All participants provided written informed consent and their responses were confidentially stored; data collected were de-identified.

RESULTS

Participant Characteristics

We invited 108 HCWs, of whom 80 were enrolled for training that took place between 15th and 23rd January 2018. The remaining 28 HCWs did not attend the training as planned for unknown reasons. All 80 participants completed the training and the survey before and immediately after the training. Sixty-one completed the later exit survey; we were unable to locate the remaining 19 participants. The exit surveys were completed between June and November 2018. Characteristics of the 19 participants who we were unable to locate for exit surveys are shown in Table 1. Their characteristics were largely similar to those participating in the exit surveys with the exception that relatively more were midwives compared to nurse/counselors.

Participant characteristics are presented in Table 1. HCWs reflected urban (N = 24, 30%), peri-urban (N = 30, 37%), and rural (N = 26, 33%) areas. Most were nurse counselors (N = 52, 65%), while 15 (18%) were medical/clinical officers, 4 (5%) were midwives, 3 (4%) were administrators, 3 (4%) were laboratory personnel, and 3 (4%) were pharmacists. Most (N = 47, 59%) were from health centers or dispensaries, 20 (25%) were from district hospitals, and 13 (16%) were from other facilities. Fifteen in-depth interviews were conducted among six nurse counselors, four medical/clinical officers, three pharmacists and two laboratory personnel.

HIV Prevention Knowledge

As shown in Table 2, before training, HCWs reported that the information they gave to clients about HIV prevention was most commonly condom use (N = 74, 93%), abstinence (N = 41, 51%), post-exposure prophylaxis (N = 35, 44%), ART adherence (N = 28, 35%), and safe male circumcision and faithfulness (both N = 24, 30%). An increasing proportion of HCWs indicated they gave clients information about PrEP at each subsequent survey (N = 15, 19% vs. N = 20, 25% vs. N = 23, 38%; p = 0.04), although this information did not reach most clients. Increases were also seen regarding provision of information about other
TABLE 1 | Participant characteristics.

| Work location    | Pre- and post- training survey $(N = 80)$ | Exit surveys $(N = 61)$ | $p$-value | Lost to Follow-up $(N = 19)$ | Qualitative $(N = 15)$ |
|------------------|------------------------------------------|------------------------|-----------|-------------------------------|------------------------|
| Urban            | 24 (30%)                                 | 18 (29%)               | 0.81      | 6 (32%)                       |                         |
| Peri-urban       | 30 (37%)                                 | 26 (43%)               |           | 4 (21%)                       | (N = 15)               |
| Rural            | 26 (33%)                                 | 17 (28%)               |           | 9 (47%)                       | (N = 15)               |
| Workstation      |                                          |                        |           |                               |                        |
| District hospital| 20 (25%)                                 | 12 (20%)               | 0.93      | 8 (42%)                       |                         |
| Health center or dispensary| 47 (59%) | 38 (62%)                     | 9 (47%)   |                               |                         |
| National referral hospital| 4 (5%)      | 4 (6%)                      | 0 (0%)    |                               |                         |
| Private not-for-profit organization| 6 (7%)       | 4 (6%)                      | 2 (11%)   |                               |                         |
| Non-governmental organization| 3 (4%)       | 3 (5%)                      | 0 (0%)    |                               |                         |
| Cadre            |                                          |                        |           |                               |                        |
| Administration   | 3 (4%)                                   | 2 (3%)                 | 0.65      | 1 (5%)                        | (N = 15)               |
| Medical/clinical officer| 15 (18%)    | 10 (16%)                   | 5 (26%)   | 4 (27%)                       |                         |
| Nurse counselors | 52 (65%)                                 | 44 (72%)               | 9 (47%)   | 9 (60%)                       |                         |
| Midwife          | 4 (5%)                                   | 0 (0%)                 | 3 (16%)   | 2 (13%)                       |                         |
| Laboratory personnel| 3 (4%)       | 3 (5%)                      | 0 (0%)    | 0 (0%)                        |                         |
| Pharmacist       | 3 (4%)                                   | 2 (3%)                 | 1 (5%)    | 0 (0%)                        |                         |
| Workstation experience (years) |                                      |                        |           |                               |                        |
| <3 years         | 31 (39%)                                 | 24 (39%)               | 0.86      | 8 (42%)                       | 2 (13%)                |
| 3–6 years        | 32 (40%)                                 | 22 (36%)               | 7 (37%)   | 10 (67%)                      |                         |
| >6 years         | 17 (21%)                                 | 15 (25%)               | 4 (21%)   | 3 (20%)                       |                         |
| HIV-related work experience (years) |                                      |                        |           |                               |                        |
| <3 years         | 23 (29%)                                 | 12 (20%)               | 0.31      | 9 (47%)                       |                         |
| 3–6 years        | 33 (41%)                                 | 24 (39%)               | 5 (26%)   |                               |                         |
| >6 years         | 24 (30%)                                 | 25 (41%)               | 5 (26%)   |                               |                         |

HIV prevention tools (i.e., abstinence, safe male circumcision, sexually transmitted infections, and elimination of mother to child HIV transmission); however, they decreased to some extent by the exit survey. Notably, several topics, including family planning and routine HIV testing, were not commonly discussed with clients.

In qualitative interviews, HCWs indicated their knowledge of HIV prevention through descriptions of the information they provided to persons at risk for HIV. When referencing the period before their training, HCWs talked about combination prevention including condoms, ART for prevention (i.e., prevention of secondary transmission), abstinence, treatment of sexually transmitted infections, HIV testing, and post-exposure prophylaxis.

“I would emphasize condom use, though it has its challenges because some people pull them off in the process. I would also encourage the couple to adhere well to the drugs and also for the couples to support each other like negative partner to encourage the positive partner to adhere well to the drugs because if the positive person is taking the drugs well, the chances of infection are low….” (Nurse counselor: #04)

“…abstain if it is possible. Also to test and treat sexually transmitted infections promptly, and we also tell them to have sex with a partner with whom you have tested for HIV. Also, a person who has encountered a problem, for example when she has been raped or when he has had a needle prick, we encourage that person to take the medicine which is swallowed [PEP] to prevent one from acquiring HIV. (Nurse counselor: #08)"

There was, however, a shift in information given about HIV prevention services after the training on PrEP. In addition to the other options, HCWs described including PrEP to the available HIV prevention messaging, particularly for HIV serodifferent couples.

“Ever since we got the training, at least discordant couples we have been getting, we have been sharing with them. We have been passing on the information although drugs [PrEP] have not been here. Every time clients come to the health facility, we give them updates about PrEP. We keep telling them that there is a drug [PrEP] that can help the negative person to remain negative. Since we know there is PrEP, we encourage them to bring their partners to test and if found negative they can be offered PrEP and remain negative. The positive partner is started on ARVs on that day and then the negative is started on PrEP”. (Medical officer: #10)

“We have had scenarios where some male partners come to us asking for the drug and telling us that, ‘I have come to pick the drug. My wife is HIV positive and I wouldn’t want to leave her.’"
TABLE 2 | HIV prevention knowledge.

| HIV testing and counseling information given to clients about HIV prevention* | Pre-training survey (N = 80) | Post-training survey (N = 80) | Exit survey (N = 61) | Fisher’s exact p-value |
|---|---|---|---|---|
| Condom use | 74 (93%) | 73 (91%) | 57 (93%) | 0.89 |
| Abstinence | 41 (61%) | 56 (70%)<sup>∧</sup> | 30 (49%) | 0.02 |
| Post-exposure prophylaxis | 35 (44%) | 49 (61%)<sup>∧</sup> | 34 (56%) | 0.08 |
| Safe male circumcision | 24 (30%) | 48 (60%)<sup>∧</sup> | 25 (41%) | 0.001 |
| ART uptake and adherence | 28 (35%) | 40 (50%)<sup>∧</sup> | 24 (39%) | 0.15 |
| STI treatment | 14 (17%) | 32 (40%)<sup>∧</sup> | 14 (23%) | 0.005 |
| PrEP | 15 (19%) | 20 (25%) | 23 (38%)<sup>∧</sup> | 0.04 |
| Faithfulness | 24 (30%) | 17 (21%) | 11 (18%) | 0.20 |
| Safer sex/ risk reduction | 18 (22%) | 17 (21%) | 11 (18%) | 0.80 |
| EMTCT | 4 (5%) | 28 (35%)<sup>∧</sup> | 11 (18%)<sup>∧</sup> | <0.001 |
| Family planning | 9 (11%) | 12 (15%) | 4 (8%) | 0.29 |
| Routine testing | 7 (9%) | 5 (8%) | 2 (3%) | 0.48 |
| Partner HIV testing and disclosure | 4 (5%) | 2 (2%) | 6 (10%) | 0.16 |
| Not sharing sharps | 4 (5%) | 2 (2%) | 5 (8%) | 0.31 |

STI, sexually transmitted infections; EMTCT, elimination of mother to child transmission.

*Multiple response questions; boldface indicates statistical significance (p < 0.05).
<sup>∧</sup> Indicates that this value is significant in comparison with the pre-training value in a post-hoc analysis of the Fisher’s exact test.

So I always tell them to wait a bit (whispers), and it is a challenge because you are giving out information when you are not yet ready”. (Nurse counselor: #05)

HCWs noted the challenge in generating demand in anticipation of providing PrEP when it was not yet available; however, they were enthusiastic about ultimately adding PrEP to the available HIV prevention tools and expressed a desire to make it available to their clientele.

PrEP Knowledge and Willingness to Prescribe PrEP

Table 3 indicates knowledge and beliefs about PrEP. We saw a significant and largely sustained increase across the surveys in the knowledge of PrEP as an HIV prevention tool, although nearly half of HCWs did not describe PrEP in this way in the exit survey (N = 25, 31% vs. N = 48, 60% vs. N = 33, 54%; p < 0.001). HCWs most commonly saw PrEP as benefitting sex workers and HIV serodifferent couples. After the training, more HCWs also reported PrEP as beneficial for other key populations, such as MSM, fisher folk, and truckers. However, some decreases were seen with time and less than half of HCWs felt these other populations would benefit from PrEP in the exit survey. General knowledge of PrEP was high and increased over time. Most HCWs knew that PrEP should be used during periods of risk for HIV acquisition (N = 34, 43% vs. N = 73, 91% vs. N = 42, 69%; p < 0.001). Significant increases were seen in the proportion of HCWs indicating that PrEP was for HIV-negative people (N = 31, 39% vs. N = 55, 69% vs. N = 39, 64%; p < 0.001) and that PrEP was to be used before HIV exposure (N = 23, 29% vs. N = 41, 51% vs. N = 22, 36%; p = 0.01), although large knowledge gaps in these areas remained. A significant decrease was seen in HCWs who thought PrEP would cause drug resistance (N = 38, 61% vs. N = 9, 11% vs. N = 18, 30%; p < 0.001). HCWs felt counseling would be the best way to help clients adhere to PrEP (N = 52, 65% vs. N = 67, 84% vs. N = 47, 77%; p = 0.02).

In the qualitative interviews, HCWs expressed their understanding of PrEP through descriptions of what they told clients in anticipation of providing PrEP. They explained, for instance, that PrEP should be taken daily, at the same time, during periods of “high risk.”

"The negative partner is the one who takes PrEP. And I always tell the couple the duration of taking PrEP which is for as long as the negative partner is still at risk of getting infected. I encourage the couple to adhere well to the drugs by taking the drugs daily since the couple is at high risk of getting infected and must keep the time of taking the drugs." (Nurse counselor: #04)

HCWs also identified key populations at substantial risk of HIV as potential candidates for taking PrEP.

"We tell them [clients] it’s a drug given to a negative person to prevent them from acquiring HIV... it is supposed to be given to people at high risk of getting infection, example of key populations like sex workers, men to men, long distance truckers, fisher folks, boda-boda men [motorcycle taxi riders] and discordant couples and as long as you are at high risk. (Medical officer: #10)

HCWs explained the function of PrEP, often in reference to antiretroviral therapy and using analogies to convey their understanding. They indicated trust in its effectiveness, especially if potential PrEP users took it as prescribed.
TABLE 3 | PrEP knowledge and willingness to prescribe PrEP.

|                          | Pre-training survey | Post-training survey | Exit survey | Fishers exact p-value |
|--------------------------|---------------------|----------------------|-------------|-----------------------|
|                          | $N = 80$            | $N = 80$             | $N = 61$    |                       |
| HCW ever heard of PrEP (yes/no)** | 62 (78%)            | 80 (100%)           | 61 (100%)   | $<0.001$              |
| PrEP is a tool for HIV prevention (yes/no) | 25 (31%)            | 48 (60%)            | 33 (54%)    | 0.001                 |
| HCW knowledge about who can benefit from PrEP** | $N = 62$            | $N = 80$             | $N = 61$    |                       |
| Discordant couples       | 48 (77%)            | 71 (89%)*           | 53 (87%)*   | $<0.001$              |
| MSM                      | 14 (23%)            | 44 (55%)*           | 26 (46%)*   | $<0.001$              |
| Fisher folk              | 22 (35%)            | 38 (48%)*           | 21 (34%)    | 0.03                  |
| Sex workers              | 51 (82%)            | 78 (96%)*           | 56 (92%)*   | 0.006                 |
| Transgender individuals  | 1 (2%)              | 7 (9%)              | 0 (0%)      | 0.01                  |
| People who use drugs     | 4 (6%)              | 14 (18%)*           | 3 (5%)      | 0.02                  |
| Truckers                 | 16 (26%)            | 41 (51%)*           | 23 (38%)*   | $<0.001$              |
| Sex worker clients       | 5 (8%)              | 3 (4%)              | 3 (5%)      | 0.93                  |
| Sexual violence survivors| 1 (2%)              | 0 (0%)              | 1 (2%)      | 0.73                  |
| Information about PrEP that HCW give clients* | $N = 80$            | $N = 80$             | $N = 61$    |                       |
| PrEP is for HIV-uninfected people | 31 (39%)            | 55 (69%)*           | 39 (64%)*   | $<0.001$              |
| PrEP is before exposure  | 23 (29%)            | 41 (51%)*           | 22 (36%)    | 0.01                  |
| PrEP uses ARVs           | 16 (20%)            | 17 (21%)            | 7 (11%)     | 0.30                  |
| PrEP is for people at high risk | 9 (11%)            | 16 (20%)*           | 22 (36%)*   | 0.002                 |
| PrEP is short-term       | 8 (10%)             | 12 (15%)            | 7 (11%)     | 0.61                  |
| Effective for HIV prevention | 4 (5%)              | 14 (18%)*           | 6 (10%)     | 0.035                 |
| PrEP side effects        | 2 (3%)              | 2 (3%)              | 1 (2%)      | 1.00                  |
| PrEP does not prevent STI*^ | 0 (0%)              | 6 (8%)              | 0 (0%)      | 0.004                 |
| HCW knowledge on duration of PrEP use | $N = 80$            | $N = 80$             | $N = 61$    |                       |
| During periods of HIV risk (yes/no) | 34 (43%)            | 73 (91%)*           | 42 (69%)    | $<0.001$              |
| Life-long (yes/no)       | 8 (10%)             | 1 (1%)              | 2 (3%)      | 0.03                  |
| Within 3 months (1-3 months) (yes/no) | 7 (9%)             | 1 (1%)              | 2 (3%)      | 0.07                  |
| Within 1 year (6 months - 1 year) (yes/no) | 2 (3%)            | 4 (5%)              | 12 (20%)    | 0.001                 |
| Factors not associated with PrEP use** | $N = 62$            | $N = 80$             | $N = 61$    |                       |
| PrEP can promote unsafe sex | 39 (63%)            | 31 (39%)            | 32 (52%)    | 0.23                  |
| PrEP causes drug resistance | 38 (61%)            | 9 (11%)*            | 18 (30%)*   | $<0.001$              |
| PrEP has “bad side effects” | 35 (56%)            | 26 (33%)            | 16 (26%)    | 0.08                  |
| PrEP can immunize one from HIV | 11 (18%)            | 13 (16%)            | 12 (20%)    | 0.63                  |
| PrEP is taken for 28 days | 6 (10%)             | 8 (10%)             | 4 (7%)      | 0.82                  |
| PrEP is not very effective at protecting against HIV | 6 (10%)            | 5 (6%)              | 3 (5%)      | 0.94                  |
| PrEP is given after exposure | 4 (6%)              | 5 (6%)              | 4 (7%)      | 0.94                  |
| How HCWs would help people adhere to PrEP* | $N = 80$            | $N = 80$             | $N = 61$    |                       |
| Counseling               | 52 (65%)            | 67 (84%)*           | 47 (77%)    | 0.02                  |
| Reminders                | 17 (21%)            | 22 (28%)            | 23 (38%)    | 0.10                  |
| Pillbox                  | 5 (6%)              | 8 (10%)             | 2 (3%)      | 0.31                  |
| Explaining PrEP Benefits and Side Effects | 3 (4%)             | 8 (10%)             | 3 (5%)      | 0.30                  |
| Follow up visits and calls | 3 (4%)             | 7 (9%)              | 5 (8%)      | 0.40                  |
| Providing health education on PrEP | 1 (1%)              | 11 (14%)*           | 4 (7%)      | 0.007                 |
| Treatment support groups | 3 (4%)              | 8 (10%)             | 6 (10%)     | 0.27                  |

*Multiple response questions, boldface indicates statistical significance ($p < 0.05$).
¥Data were missing from some surveys due to nonresponse; the total available number of surveys are noted for each question.
¥Indicates that this value is significant in comparison with the pre-training value in a post-hoc analysis of the Fisher’s exact test.
¥¥The Fishers exact p-value was statistically significant but data were too sparse to fit a multinomial regression.
"I think that if PrEP is taken as prescribed, it is the best... the active drug in PrEP is the same as what is in ARVs [antiretroviral drugs] and if the drug in the antiretroviral treatment can manage to weaken the virus such that it just sleeps, then I am sure that even this PrEP can prevent one from acquiring HIV.” (Nurse counselor: #08)

“We’ll tell them that PrEP will help them if you are in a situation that can put you at risk of contracting the virus, for example when the man has been tested and he is found positive and you the woman do not have the virus you can take it. It saves one from contracting the virus especially if his copies are high and not until the virus in the man’s body has been weakened so when she is using PrEP the chances of contracting the virus are very low and she might not contract the virus at all” (Nurse counselor: #07)

Some HCW expressed concerns that PrEP might cause behavioral risk compensation and result in promiscuity or more risky sexual behavior because the risk of HIV transmission is reduced by using PrEP.

“That is my fear because people who are using PrEP know that they will not acquire the virus so my fear is that it makes someone engage into sexual intercourse with a couple of people.” (Laboratory personnel: #06)

HCWs were also worried about low adherence among the potential PrEP users, which could lead to HIV infection.

“My other worry is people might take it as a cure and relax in taking the drug so might have sexual intercourse and test positive when tested for HIV/AIDS. So, this means that they must be counseled very well.” (Nurse counselor: #05)

Overall, the HCWs indicated a high level of understanding about PrEP and were favorable about its benefits for their clients with high HIV risk, although concerns about risk compensation, stigma, and low adherence reflected hesitancy to prescribe it among some HCWs.

**Provision, Support, and Preparedness for PrEP Service Delivery**

As shown in Table 4, HCWs were generally confident that they were well staffed to provide counseling and services for HIV prevention, including PrEP, at their respective facilities after the training. Nearly all HCWs would offer or recommend PrEP if it were available. Stigma related to PrEP service delivery was well staffed to provide counseling and services for HIV prevention, including PrEP, at their respective facilities after the training. Nearly all HCWs would offer or recommend PrEP if it were available. Stigma related to PrEP service delivery to key populations was low and reduced over time ($N = 13, 16\%$ vs. $N = 17, 21\%$ and $N = 3, 5\%; p = 0.01$). Availability of PrEP as a recommended method of HIV prevention increased over time, but remained low ($N = 6, 8\%$ vs. $N = 11, 14\%$ vs. $N = 13, 21\%; p = 0.07$).

In the qualitative interviews, HCWs from different facilities expressed conflicting ideas about their health facilities’ readiness to provide PrEP. Key issues were infrastructure and human resources.

“Currently, there are some staff members who have been transferred to hospitals and therefore staff has reduced at [name of health facility], but they promised us more staff though they have not yet come. Yes, they have transferred some staff to hospitals, which means that the new staff they will bring will have to be trained about PrEP since they are new people at the site. That can be done. But for the case of infrastructure, we have buildings like the laboratory, pharmacy, and counseling rooms”. (Nurse counselor: #04)

“Yes. Although the drugs are there in the clinic already, we cannot start them on PrEP… we have to be with the books, and we have to be with everything set. We cannot just say that ‘Anyway, we have some PrEP. Let me give you some’… We are ready to give, but we don’t have the resources to do the documentation yet… We need the books. We need the lockers where we are going to store PrEP.” (Nurse counselor: #09)

To improve site readiness, HCWs preferred for PrEP to be incorporated into the existing HIV prevention structures and programs, starting from the HIV prevention messages offered during HIV testing counseling.

“…giving a talk about HTS [HIV testing services], I think even PrEP should be talked about as one of the prevention methods so that everyone will be aware that there are drugs. In case one tests negative, they can take and prevent themselves from getting HIV. It (PrEP) should be part of the package given to the people that are HIV-positive and HIV-negative.” (Medical officer: #11)

“I would prefer that it is included in the package that we give people about HTS both at community level and at the health facility too so that someone does not learn about PrEP from here only, but also when out there they can know they can access these drugs”. (Nurse counselor: #01)

Overall, HCWs felt prepared to offer PrEP from a knowledge perspective, but the practical systems for delivery and integration into routine services were not fully ready in some sites.

**DISCUSSION**

In this mixed methods study of HCWs from health facilities offering HIV primary care services across Central Uganda, standardized training based on the Uganda MoH PrEP guidelines greatly improved HCW knowledge about PrEP, although some gaps remained. The training also stimulated incorporation of PrEP into the counseling messages given to clients. HCWs were willing to prescribe PrEP to a variety of key populations, although primarily favoring HIV serodifferent couples and sex workers. Notably, adolescent girls, young women, and the general population were not included as key beneficiaries in the Uganda national guidelines at the time of the study. HCWs generally felt prepared to offer PrEP with most facilities being adequately staffed and resourced for PrEP provision. We previously reported that potential PrEP users primarily received information about HIV prevention from HCWs (16). This reliance on HCWs for information and the need for accurate knowledge to provide high-quality care highlight the importance of ongoing training as PrEP is scaled up in Uganda and elsewhere. Kenya uses the cascade approach, where national and county level “Trainer of Trainers” (ToT) are taught with a standardized curriculum, who, in turn, pass this knowledge onto
TABLE 4 | Provision, support, and preparedness for PrEP service delivery.

|                                      | Pre-training survey | Post-training survey | Exit survey | Fishers exact p-value |
|--------------------------------------|---------------------|----------------------|-------------|-----------------------|
|                                      | N = 62              | N = 80               | N = 61      |                       |
| **How well the facility is staffed to provide HIV prevention services** |                     |                      |             |                       |
| Very well                            | 28 (45%)            | 43 (54%)             | 44 (72%)*   | 0.03                  |
| Somewhat                             | 31 (50%)            | 34 (42%)             | 17 (28%)*   |                       |
| Not at all                           | 1 (2%)              | 2 (3%)               | 0 (0%)      |                       |
| Unsure                               | 2 (3%)              | 1 (1%)               | 0 (0%)      |                       |
| **How well the facility is staffed to cater for PrEP delivery** | N = 61              | N = 80               | N = 61      |                       |
| Very well                            | 30 (49%)            | 46 (57%)             | 45 (74%)*   | 0.04                  |
| Somewhat                             | 28 (46%)            | 30 (37%)             | 16 (26%)*   |                       |
| Not at all                           | 0 (0%)              | 2 (3%)               | 0 (0%)      |                       |
| Unsure                               | 3 (5%)              | 2 (3%)               | 0 (0%)      |                       |
| **If PrEP were made available, would you offer/recommend PrEP for potential users?** | N = 60              | N = 77               | N = 61      |                       |
| Yes                                  | 57 (95%)            | 76 (99%)             | 61 (100%)   | 0.15                  |
| No                                   | 3 (5%)              | 1 (1%)               | 0 (0%)      |                       |
| **Stigma in offering PrEP services to key populations** | N = 80              | N = 80               | N = 61      |                       |
| Yes                                  | 13 (16%)            | 17 (21%)*            | 3 (5%)*     |                       |
| No                                   | 67 (84%)            | 63 (79%)*            | 58 (95%)*   |                       |
| **PrEP is available as a recommended method of HIV prevention** | N = 80              | N = 80               | N = 61      |                       |
| Yes                                  | 6 (8%)              | 11 (14%)             | 13 (21%)*   | 0.07                  |
| No                                   | 74 (92%)            | 69 (86%)             | 47 (79%)*   |                       |

Boldface indicates statistical significance (p < 0.05).

*a*Data were missing from some surveys due to nonresponse; the total available number of surveys are noted for each question.

*b*HCWs were asked if they felt that either workmates, friends, or their families would stigmatize them if they prescribed PrEP.

*c*Indicates that this value is significant in comparison with the pre-training value in a post-hoc analysis of the Fisher’s exact test.

other health workers and peer educators. To maintain a high-level quality of service delivery, mechanisms like on-site training and mentorship to offer supportive supervision and ongoing monitoring and evaluation have been put in place. (18–20). Similarly, the Uganda MoH is currently scaling up countrywide HCW training for ToTs (5); in all regions, the trained trainers will then offer support to the HCWs at the facilities. From years of experience with ART service delivery across sub-Saharan Africa, the importance of refresher trainings with accountability is clear, particularly as delivery of key messages can wane with time (13). The MoH thus also plans to offer supportive supervision that entails quarterly refresher training and knowledge checks with the help of a checklist to fill some of the remaining gaps as noted in this study. Although not currently planned, additional skill sets, including motivational counseling, to support clients in selecting and utilizing preferred HIV prevention methods would also be beneficial (21).

The paradigm for HIV prevention has been changed by PrEP. PrEP delivery currently based at health facilities requires sufficient knowledge and confidence of HCWs to talk to clients about antiretroviral medications for HIV prevention. They need to explain transient side effects and give clear recommendations for safety in starting and stopping PrEP to optimize effectiveness. The concern for risk compensation among healthcare workers in our study is also notable, despite numerous studies indicating the overall low prevalence of such behaviors (22, 23). Awareness needs to be raised about this literature to prevent such concerns from limiting PrEP provision. Additionally, potential stigmatizing behavior must be addressed both from the community (24), as well as within the healthcare profession (25, 26), although stigma was reported as low among HCWs in our study. Broadening access to PrEP beyond key populations may be helpful in this regard, and many have called for widespread PrEP availability (12). In addition to training HCWs, the MoH should improve awareness of PrEP through social marketing strategies that involve civil society and engage communities in addressing myths and misconceptions and the championing of PrEP. Such efforts will complement healthcare worker training and help combat challenges to PrEP uptake, such as stigma and structural barriers in care access (27).

Although the HCW training program had many successes in conveying knowledge and guidance for PrEP use, the MoH has not yet provided resources to support all aspects of providing PrEP in all public health facilities. The discrepancies in the quantitative and qualitative data on preparedness may reflect the experience of specific cadres of HCWs. That is, some patient-facing aspects (e.g., counseling by nurses) are ready-to-go, while others (e.g., infrastructure as seen by the clinical officer) are not. The logistics supply chain, in particular, can be a challenge (5, 28), and even procurement of PrEP at the national level has been difficult. PrEP availability in Uganda was initially limited to tenofovir/emtricitabine, which was both costly and not otherwise used for ART under government programs in the country. Tenofovir/lamivudine, however, is a much more practical
and emtricitabine (22) and the widespread availability of low-cost generic formulations in the country for ART. Efforts are needed to balance the demands for this drug between ART and PrEP in a context of limited resources (10, 23); however, the tenofovir/lamivudine formulation may be critical in promoting large-scale rollout of PrEP in public health facilities (29).

This study had several strengths. First, it is among a few reports of HCW knowledge and beliefs about PrEP in sub-Saharan Africa and reflected a wide variety of cadres, health facilities, and geographic locations. Our approach enabled us to follow trends in specific knowledge and beliefs over time, while also allowing for the emergence of new ideas through open-ended interviews. Our study also has limitations. We evaluated a convenience sample of HCWs selected by the leadership of the facilities, which may have introduced sampling bias. Approximately one-fifth of HCW invited for training did not attend and we were unable to ascertain reasons for non-attendance. The relatively small number of HCWs may have also constrained our ability to see significant effects, and missing data and incomplete follow-up at study exit may have biased our findings. Given the lack of a pre-specified sample size in this exploratory study, our findings should be interpreted with caution. Additionally, we did not directly measure the quality of the information provided by healthcare workers to clients. Finally, none of the chosen facilities was providing PrEP at the time of the study. We purposely chose this population to prepare for the rollout of PrEP; however, experiences may differ when PrEP is provided as part of routine service delivery and its use becomes normalized.

CONCLUSIONS

Standardized training improved knowledge, willingness, and preparedness to offer PrEP services among most HCWs in Central Uganda; however, some deficits remained. There is need for sustainable education models that move beyond traditional didactic learning approaches to support PrEP rollout. Commitment to HCW training is a critical component of successful scale-up of health service delivery, but frequent staff turnover requires ongoing training, support supervision, and monitoring and evaluation to optimize PrEP delivery services and maintain quality assurance.

PRIOR PRESENTATION

These data were reported, in part, at the 16th International Conference on HIV Treatment and Prevention Adherence, 7-9th November 2020, (abstract # 29519).

REFERENCES

1. Chou R, Evans C, Hoverman A, Sun C, Dana T, Bougatsos C, et al. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. (2019) 321:2214–30. doi: 10.1001/jama.2019.2591

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by (1). National HIV/AIDS Research Committee (ARC 196), (2). Uganda National Council for Science and Technology (SS 4277), and Partners HealthCare/Massachusetts General Hospital (2017P000482/PHS). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

TM and JH designed the study and wrote the first draft. RN performed the statistical analyses. NW, MW, and EP designed the qualitative component of the study and wrote the interview guides. VK, BK, GN, and JB did qualitative interviews, transcriptions, coding, and qualitative analysis. All authors contributed to data collection, interpretation of the results, and the writing of the manuscript, and all approved the final draft.

FUNDING

This study was supported by the U.S. National Institute of Mental Health (grants R01MH098744 and K24MH114732 to JH). The authors designed and executed the study, had full access to the raw data, performed all analyses, wrote the manuscript, and had final responsibility for the decision to submit for publication. The funder had no role in the design, data collection, analysis, interpretation, or writing of the report.

ACKNOWLEDGMENTS

We are grateful to the HCWs for their participation and dedication. We thank the study team members at Makerere University Infectious Diseases Institute and the University of Washington for their contributions to data collection.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.658826/full#supplementary-material

2. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Kocheлин FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. Aids. (2016) 30:1973–83. doi: 10.1097/QAD.0000000000001145

3. WHO. Updated Recommendations on First-line and Second-line Antiretroviral Regimens and Post-exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV: Interim Guidelines: Supplement to the 2016
Consolidated Guidelines on the use of Antiretroviral Drugs for Treating and Preventing HIV Infection. World Health Organization (2018). Available online at: https://www.who.int/publications/i/item/WHO-CDS-HIV-2018.15 (accessed November 11, 2020).

4. Amico KR, Bekker LG. Global PrEP roll-out: recommendations for programmatic success. Lancet HIV. (2019) 6:e137–40. doi: 10.1016/S2352-3018(19)30002-5

5. Uganda MoH. Technical Guidance on Pre-Exposure Prophylaxis (PrEP) for Persons at High Risk of HIV in Uganda. Kampala, Uganda: Ministry of Health (2016).

6. Krakower DS, Mayer KH. The role of healthcare providers in the roll-out of PrEP. Curr Opin HIV AIDS. (2016) 11:41. doi:10.1097/COH.0000000000000206

7. Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers’ perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav. (2014) 18:1712–21. doi:10.1007/s10461-014-0839-3

8. Puro V, Palumieri A, De Carlì G, Piselli P, Ippolito G. Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. BMC Infect Dis. (2013) 13:217. doi: 10.1186/1471-2334-13-217

9. Pilgrim N, Jani N, Mathur V, Kahabuka C, Saria V, Makyao N, et al. Provider perspectives on PrEP for adolescent girls and young women in Tanzania: The role of provider biases and quality of care. PLoS ONE. (2018) 15:e0196280. doi: 10.1371/journal.pone.0196280

10. Lanham M, Ridgeway K, Mireku M, Nhamo D, Pillay D, Muriie M, et al. Healthcare providers’ attitudes toward and experiences delivering oral PrEP to adolescent girls and young women in Kenya, South Africa, and Zimbabwe. BMC Health Serv Res. (2021) 21:1–12. doi:10.1186/s12913-021-06978-0

11. Irungu EM, Ngure K, Mugwanya K, Mugo NR, Kiragu M, Irungu E, et al. PrEP for Africa: what we have learnt and what is needed to move to program implementation. Curr Opin HIV AIDS. (2016) 11:80–86. doi:10.1097/COH.0000000000000224

12. O’Malley G, Barnabée G, Mugwanya K. Scaling-up PrEP Delivery in Sub-Saharan Africa: What Can We Learn from the Scale-up of ART? Curr HIV/AIDS Rep. (2019) 16:141–50. doi:10.1007/s11904-019-00437-6

13. Djomand G. Expansion of HIV Preexposure Prophylaxis to 35 PEPFAR-Supported Early Program Adopters, October 2016–September 2018. MMWR Morb Mortal Wkly Rep. (2020) 69:212–5. doi:10.15585/mmwr.mm6908a3

14. MOH. Consolidated Guidelines on the Prevention and Treatment of HIV in Uganda. Kampala, Uganda: Ministry of Health (2018). Available online at: http://library.health.go.ug/publications/hivaidss/consolidated-guidelines-prevention-and-treatment-hiv-uganda (accessed November 11, 2020).

15. Mwonge TR, Nsubuga R, Brown C, Nakyanzi A, Bagaya M, Bambia F, et al. Knowledge and barriers of PrEP delivery among diverse groups of potential PrEP users in Central Uganda. PLoS ONE. (2020) 15:e0241399. doi: 10.1371/journal.pone.0241399

16. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. (2005) 15:1277–88. doi:10.1177/1049732305276687

17. Reza-Paul S, Lazarus L, Jana S, Ray P, Mugo N, Ngure K, et al. (2019). Community Inclusion in PrEP Demonstration Projects: Lessons for Scaling Up. Gates Open Research 3.

18. Irungu EM, Baeten JM. PrEP rollout in Africa: status and opportunity. Nat Med. (2020) 26:655–64. doi:10.1038/s41591-020-0872-x

19. Larsen A, Wilson KS, Kinuthia J, John-Stewart G, Richardson B, Pintye J, et al. Standardised patient encounters to improve quality of counselling for pre-exposure prophylaxis (PrEP) in adolescent girls and young women (AGYW) in Kenya: study protocol of a cluster randomised controlled trial. BMJ Open. (2020) 10:e035689. doi: 10.1136/bmjopen-2019-035689

20. Celum CL, Delany-Morett L, Baeten JM, van der Straten A, Hosek S, Bukusi EA, et al. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. (2019) 22:e25298. doi:10.1002/jia2.25298

21. Mugwanya KK, Donnell D, Celum C, Thomas KK, Ndase P, Mugo N, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis. (2013) 13:1021–8. doi:10.1016/S1473-3099(13)70226-3

22. Roberts DA, Hawes SE, Bao MDB, Ndiaye AY, Gueye D, Rauge DN, et al. Trends in reported sexual behavior and Y-chromosomal DNA detection among female sex workers in the Senegal preexposure prophylaxis demonstration project. Sex Transm Dis. (2020) 47:314. doi:10.1097/OLQ.0000000000001175

23. Brooks RA, Nieto O, Landrian A, Donohoe TJJ. Persistent stigmatizing and negative perceptions of pre-exposure prophylaxis (PrEP) users: implications for PrEP adoption among Latino men who have sex with men. AIDS Care. (2019) 31:427–35. doi:10.1080/09540121.2018.1499864

24. Camlin CS, Koss CA, Getahun M, Owindo I, Hikakhorit H, Akitakcsa W, et al. Understanding demand for PrEP and early experiences of PrEP use among young adults in rural Kenya and Uganda: a qualitative study. AIDS Behav. (2020) 24:2149–62. doi:10.1007/s10461-020-02780-x

25. Calabrese SK. Understanding, Contextualizing, and Addressing PrEP Stigma to Enhance PrEP Implementation. Curr HIV/AIDS Rep. (2020) 17:579–88. doi:10.1007/s11904-020-00533-y

26. Emmanuel G, Folayan M, Undelikwe G, Ochonye B, Jayeoba T, Yusuf A, et al. Community perspectives on barriers and challenges to HIV pre-exposure prophylaxis access by men who have sex with men and female sex workers access in Nigeria. BMC Public Health. (2020) 20:1–10. doi:10.1186/s12889-020-8195-x

27. PEPFAR. Uganda Country Operational Plan (COP) 2020. Strategic Direction Summary, President’s Emergency Plan for AIDS Relief (2020). Available online at: https://healthgap.org/wp-content/uploads/2020/02/Peoples-Voice-Uganda-COP20.pdf (accessed November 11, 2020).

28. Mujuigira A, Baeten JM, Hodges-Mameletzis I, Haberer JE. Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen. Drugs. (2020) 80:1881–8. doi:10.1007/s40265-020-01419-4

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Mwonge, Nsubuga, Ware, Wyatt, Pisarski, Kamusimzi, Kasita, Nalukwago, Brown, Nakyanzi, Bagaya, Bambia, Szelubiala, Katahira, Kyambadde, Baeten, Heffron, Celum, Mugyera and Haberer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.